Synthekine Stock

Synthekine is a development stage biotherapeutics company focused on the engineering of novel specific and potent cytokine therapies.

Sign up today and learn more about Synthekine Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Synthekine Stock

Synthekine is an engineered cytokine therapeutics company that creates selective immunotherapies to improve cancer and inflammatory disease treatment paradigms. Using knowledge of cytokine structure and function, the company develops therapeutics that maximize cytokine efficacy while avoiding toxic side effects. Synthekine is developing a broad and deep pipeline of product candidates by leveraging principles of cytokine partial agonism and immunological specificity across multiple protein engineering platforms. Modified cytokines, cytokine-enhanced cell therapies, and surrogate cytokine agonists are among the novel immunotherapies.

Funding History

September 2020$82.0M
June 2021$108M
January 2023$100M

Management

Chief Executive Officer

Debanjan Ray

Board Member

Julie Papanek Grant

Founder

K. Christopher Garcia

Board Member

Srinivas Akkaraju

Independent Member

Nils Lonberg

Chief Development Officer

Martin Oft

Board Member

Mardi C. Dier

Board Member

Tim Kutzkey

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo